A Study of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin) in Participants With Solid Tumors

Summary

The primary objective of this study is to evaluate the tolerability and safety profile of farletuzumab ecteribulin in participants with solid tumors.

Timeline

Start

2017-11-28

Primary completion

2022-10-26

Completion

2022-10-26

Publications

• Yoshida T, Kozuki T, Ikezawa H, Yusa W, Miura T, Otake Y, Nishio M. Safety and Antitumor Activity of Farletuzumab Ecteribulin in Patients With NSCLC: Phase I Expansion Results. JTO Clin Res Rep. 2026 Jan 30;7(4):100962. doi: 10.1016/j.jtocrr.2026.100962. eCollection 2026 Apr.
• Yonemori K, Yunokawa M, Matsumoto K, Takehara K, Hasegawa K, Hirashima Y, Kato H, Ikezawa H, Otake Y, Yusa W, Miura T, Nishio S. Clinical trial of safety and antitumor activity of farletuzumab ecteribulin in patients with platinum-resistant ovarian cancer: Phase I expansion results. Int J Gynaecol Obstet. 2026 Jun;173(3):1334-1342. doi: 10.1002/ijgo.70676. Epub 2025 Dec 23.
• Shimizu T, Fujiwara Y, Yonemori K, Koyama T, Sato J, Tamura K, Shimomura A, Ikezawa H, Nomoto M, Furuuchi K, Nakajima R, Miura T, Yamamoto N. First-in-Human Phase 1 Study of MORAb-202, an Antibody-Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-alpha-Positive Advanced Solid Tumors. Clin Cancer Res. 2021 Jul 15;27(14):3905-3915. doi: 10.1158/1078-0432.CCR-20-4740. Epub 2021 Apr 29.

Drugs

Indications